Journal
OCULAR IMMUNOLOGY AND INFLAMMATION
Volume 20, Issue 6, Pages 394-405Publisher
TAYLOR & FRANCIS INC
DOI: 10.3109/09273948.2012.726392
Keywords
Uveitis; Gene therapy; Adeno-associated virus; Lentivirus; Adenovirus
Categories
Funding
- Medical Research Council
- Dunhill Medical Foundation
- Underwood Trust
- National Institute of Health Research BMRC for Ophthalmology
- MRC [G1100383] Funding Source: UKRI
- Fight for Sight [1371/72] Funding Source: researchfish
- Medical Research Council [G1100383] Funding Source: researchfish
Ask authors/readers for more resources
Noninfectious intraocular inflammatory disease remains a significant cause of visual loss, even with current systemic immunosuppression. Alternative novel treatments are thus required, particularly for severe forms of posterior uveitis. Encouraging results from several phase I/II clinical trials of gene therapy for monogenic retinal disorders have paved the way for the development of this approach for other ocular conditions. Gene therapy for uveitis offers the possibility of potent, self-regulating, long-term disease control following a single treatment and without systemic side effects. To date, gene therapy approaches using interleukin-10, interleukin-1 receptor antagonist, interferon-alpha, soluble TNF-alpha receptors, and alpha-MSH gene transfer have been used successfully to attenuate experimental animal models of uveitis. This review evaluates these preclinical studies, considers the route to clinical application, and explores future targets and approaches.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available